In this study, we demonstrate the application of NILV‐S/MAR‐based vectors for transgene expression, target gene down‐regulation (shRNA‐mediated RNA interference), and the feasibility in generating CD19 CAR T cells for cancer immunotherapy. Here, CD19 is linked to cancer.